Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
12 hedge funds and large institutions have $11.7M invested in Soleno Therapeutics in 2017 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 4 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
64% more capital invested
Capital invested by funds: $7.13M → $11.7M (+$4.6M)
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
16.28% more ownership
Funds ownership: 18.55% → 34.83% (+16%)
0% more funds holding
Funds holding: 12 → 12 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$5.69M |
| 2 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$333K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$256K |
| 4 |
BlackRock
New York
|
+$60.6K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
+$43.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$288K |
| 2 |
BG
Bollard Group
Boston,
Massachusetts
|
-$13.6K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$12K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$5K |
SLNO Hedge Fund Activity: Q1 2017 in Review
12 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q1 2017, worth a combined $11.7M — up 64% from $7.13M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new SLNO positions and 4 closed out — a net gain of 2 holders — while 5 added to existing stakes and 1 trimmed.
The largest buyer was Vivo Capital, adding an estimated $5.69M. The largest seller was Anson Funds Management, exiting entirely with an estimated $288K sold.
- 12 institutional investors held Soleno Therapeutics (SLNO) as of Q1 2017, unchanged from Q4 2016.
- Funds reported $11.7M of Soleno Therapeutics stock for Q1 2017, up 64% quarter-over-quarter.
- 6 funds opened new Soleno Therapeutics positions in Q1 2017 and 4 closed out, a net change of +2 holders.
- The largest Soleno Therapeutics buyer in Q1 2017 was Vivo Capital, an estimated $5.69M added.
- The largest Soleno Therapeutics seller in Q1 2017 was Anson Funds Management, an estimated $288K sold.
Based on aggregated 13F filings for Q1 2017.